Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis

Imagem de Miniatura
Arquivos
art_VIANA_Myositis_specific_and_myositis_associated_autoantibody_profiles_and_2013.PDF (280.21 KB)
Citações na Scopus
102
Tipo de produção
article
Data de publicação
2013
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
CRUELLAS, Marcela Gran Pina
Citação
CLINICS, v.68, n.7, p.909-914, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: To analyze the prevalence of myositis-specific and myositis-associated autoantibodies and their clinical correlations in a large series of patients with dermatomyositis/polymyositis. METHOD: This cross-sectional study enrolled 127 dermatomyositis cases and 95 polymyositis cases. The disease-related autoantibody profiles were determined using a commercially available blood testing kit. RESULTS: The prevalence of myositis-specific autoantibodies in all 222 patients was 34.4%, whereas myositis-associated autoantibodies were found in 41.4% of the patients. The most frequently found autoantibody was anti-Ro-52 (36.9%), followed by anti-Jo-1 (18.9%), anti-Mi-2 (8.1%), anti-Ku (4.1%), anti-SRP (3.2%), anti-PL-7 (3.2%), anti-PL-12 (2.7%), anti-PM/Scl75 (2.7%), and anti-PM/Scl100 (2.7%). The distributions of these autoantibodies were comparable between polymyositis and dermatomyositis, except for a higher prevalence of anti-Jo-1 in polymyositis. Anti-Mi-2 was more prevalent in dermatomyositis. Notably, in the multivariate analysis, anti-Mi-2 and anti-Ro-52 were associated with photosensitivity and pulmonary disorders, respectively, in dermatomyositis. Anti-Jo-1 was significantly correlated with pulmonary disorders in polymyositis. Moreover, anti-Ro-52 was associated with anti-Jo-1 in both diseases. No significant correlation was observed between the remaining autoantibodies and the clinical and/or laboratory findings. CONCLUSIONS: Our data are consistent with those from other published studies involving other populations, although certain findings warrant consideration. Anti-Ro-52 and anti-Jo-1 were strongly associated with one another. Anti-Ro-52 was correlated with pulmonary disorders in dermatomyositis, whereas anti-Jo-1 was correlated with pulmonary alterations in polymyositis.
Palavras-chave
Dermatomyositis, Idiopathic Inflammatory Myopathies, Myositis-Associated Autoantibodies, Myositis-Specific Autoantibodies, Polymyositis
URI
https://observatorio.fm.usp.br/handle/OPI/4440
Referências
  1. BENCHETRIT E, 1990, ARTHRITIS RHEUM, V33, P349, DOI 10.1002/art.1780330307
  2. Betteridge Z, 2007, RHEUMATOLOGY, V46, P1005, DOI 10.1093/rheumatology/kem045
  3. BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706
  4. BUNN CC, 1986, J EXP MED, V163, P1281, DOI 10.1084/jem.163.5.1281
  5. Chinoy H, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1862
  6. Feldman BM, 2008, LANCET, V371, P2201, DOI 10.1016/S0140-6736(08)60955-1
  7. Greenberg SA, 2008, SEMIN NEUROL, V28, P241, DOI 10.1055/s-2008-1062267
  8. Guirardello A, 2010, RHEUMATOLOGY, V49, P2370, DOI 10.1093/RHEUMAT0L0GY/KEQ281
  9. Guirardello A, 2006, AUTOIMMUNITY, V39, P217, DOI 10.1080/08916930600622645
  10. Gunawardena H, 2009, RHEUMATOLOGY, V48, P607, DOI 10.1093/rheumatology/kep078
  11. HANISSIAN AS, 1982, J RHEUMATOL, V9, P390
  12. Hashish L, 2004, ARTHRITIS RHEUM, V50, P209
  13. Hengstman GJD, 2002, J NEUROL, V249, P69, DOI 10.1007/PL00007850
  14. Hirakata M, 1993, J CLIN INVEST, V91, P2556
  15. ISENBERG D, 1987, ARTHRITIS RHEUM, V30, P1320, DOI 10.1002/art.1780301124
  16. Kao AH, 2004, ARTHRITIS RHEUM, V50, P209, DOI 10.1002/art.11484
  17. Koenig M, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2276
  18. Kubo M, 2002, J AM ACAD DERMATOL, V47, P148, DOI 10.1067/mjd.2002.121037
  19. La Corte R, 2006, AUTOIMMUNITY, V39, P249, DOI 10.1080/08916930600623791
  20. LOVE LA, 1991, MEDICINE, V70, P360
  21. Marie I, 2012, SEMIN ARTHRITIS RHEU, V41, P890, DOI 10.1016/j.semarthrit.2011.09.008
  22. MATHEWS MB, 1984, J EXP MED, V160, P420, DOI 10.1084/jem.160.2.420
  23. Matsushita T, 2007, J RHEUMATOL, V34, P1012
  24. Mimori T, 2007, CURR OPIN RHEUMATOL, V19, P523, DOI 10.1097/BOR.0b013e3282f01a8c
  25. Nagaraju K, 2003, RHEUMATOLOGY, P1523
  26. NISHIKAI M, 1980, ARTHRITIS RHEUM, V23, P881, DOI 10.1002/art.1780230802
  27. O'Hanlon TP, 2006, MEDICINE, V85, P111, DOI 10.1097/01.md.0000217525.82287.eb
  28. Plotz PH, 1994, MANUAL BIOL MARKERS
  29. REEVES WH, 1986, P NATL ACAD SCI USA, V83, P9507, DOI 10.1073/pnas.83.24.9507
  30. Rutjes SA, 1997, CLIN EXP IMMUNOL, V109, P32, DOI 10.1046/j.1365-2249.1997.4081308.x
  31. Selva-O'Callaghan A, 2006, ARTHRIT RHEUM-ARTHR, V55, P791, DOI 10.1002/art.22237
  32. TARGOFF IN, 1990, ARTHRITIS RHEUM, V33, P1361, DOI 10.1002/art.1780330908
  33. TARGOFF IN, 1993, J CLIN INVEST, V91, P2556, DOI 10.1172/JCI116493
  34. Targoff IN, 2006, ARTHRITIS RHEUM, V54, P3682, DOI 10.1002/art.22164
  35. TARGOFF IN, 1992, ARTHRITIS RHEUM, V35, P821, DOI 10.1002/art.1780350718
  36. Targoff IN, 2002, RHEUM DIS CLIN N AM, V28, P859, DOI 10.1016/S0889-857X(02)00032-7
  37. TARGOFF IN, 1985, ARTHRITIS RHEUM, V28, P796, DOI 10.1002/art.1780280711
  38. Vancsa A, 2010, JOINT BONE SPINE, V77, P125, DOI 10.1016/j.jbspin.2009.08.008
  39. Wang HB, 2001, NUCLEIC ACIDS RES, V29, P2517, DOI 10.1093/nar/29.12.2517
  40. Yamagata H, 1986, Scand J Rheumatol Suppl, V61, P98

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/17